Exit-CVD project

A European Initiative
to Transform
Cardiovascular Disease

From a Terminal Pathway into a Preventable and Reversible Condition

42 partners from 17 countries unite in a landmark public-private partnership to identify critical "exit points" that can halt heart disease progression.

Discover the Project
0 Partner Organisations
0 Countries
0 Clinical Studies

The Challenge

Rethinking the Cardiovascular
Disease Continuum

Cardiovascular disease remains the leading cause of death in Europe. While decades of research show that cardiovascular disease develops progressively over time, healthcare systems still often intervene too late — after irreversible damage has already occurred.

The Continuum

Three exit points where intervention changes everything

The project focuses on identifying critical “exit points” along the cardiovascular disease continuum — moments where timely, personalised intervention can slow, stop, or even reverse disease progression before severe outcomes occur.

Learn more

Our Approach

Five pillars of innovation transforming cardiovascular care.

Medical research, artificial intelligence, advanced diagnostics, digital monitoring, and regenerative therapies — working together.

01

Early Detection

AI-enhanced monitoring and wearable technologies enable earlier identification of cardiovascular risk factors before symptoms escalate.

AI · Wearables
Prof. dr. Pim van der Harst

A Shared Vision for the Future

Our vision is a future where heart disease is no longer an irreversible pathway.
By understanding both the biological and social drivers of cardiovascular disease,
and deploying integrated innovations across diagnostics, monitoring, and care,
we can empower patients and clinicians to exit the disease continuum before it's too late.

Prof. dr. Pim van der Harst Project Coordinator of EXIT-CVD · University Medical Center Groningen

42 Partners · 17 Countries

Built Through Collaboration

A pan-European public-private consortium spanning 17 countries across Europe and North America.

By the Numbers

The Scale of EXIT-CVD

0 Partner Organisations Academic, MedTech, Pharma, SMEs & Societies
0 Countries Europe + Canada & USA
0 Clinical Studies Across all exit points